


promaxo



The History of Prostate Biopsy

From Perineal techniques to MRgBx in the office




A. ASTRALDI

1st finger-guided transrectal prostate biopsy

1926

H. HAMPTON YOUNG

1st open perineal technique for prostate biopsy



1937




K. HODGE, J. MCNEAL, & T. STAMEY

1st modern TRUS biopsy of the prostate

1989

J. STEYN & F. SMITH

1st study of the prostate using MRI



1982



A. VOHRA & D. KUMAR

Promaxo founded – 1st office-based MRI for the urologist

2008

A. VOHRA & D. KUMAR

1st MR-TRUS fusion prostate biopsy device to receive FDA clearance

2016




2020

J. ADAMS

1st Promaxo MRI-guided prostate biopsy performed in a urologist's practice

The Promaxo Journey

A History of Innovation



Headquartered in the
San Francisco Bay Area

Sales spanning **27** states &
4 countries
250+ patents



Limitations of Traditional MRI

"MRI is the undisputed gold standard for imaging soft tissue structures."

~Dr. David W. Lee,
Professor of Radiology
at Cornell University

But traditional MRI
comes with several key
limitations

Limited Reach | Low Versatility | Expensive



Extensive Infrastructure

Shielding, large footprint, floor reinforcement




Low Availability

Only 39 MRIs per million population in the US and 5 MRIs per million globally



Long Wait Times

Average wait time of 2-4 weeks for non-emergency situations



High Cost

High cost to acquire and maintain



Operations and Safety Concerns

Quenching, cryogenics, limited compatibility with robots and interventional tools



Patient Discomfort

Claustrophobia, loud noises


Promaxo Solutions

Bring MR-Guided Intervention

To your clinic and Raise the Bar on Patient Experience



Bring in-office MRI **imaging** and **guidance** platform to your Office/ASC/OR



Deliver superior **patient experience** with TP **biopsies** and expand into **treatment**




Drive better **patient outcomes** and earn lucrative **ROI** with reimbursements



Affordable solutions with multiple purchasing/financing options


The Promaxo Ecosystem Manages Entire Patient Care Continuum

Robot for Guidance* | AI-Based Tissue Characterization*



Screening*


Data collection to develop screening protocols



Diagnosis

MR guided TP biopsies (manual and robotic*)

Ground truth data collection to develop tissue characterization



Treatment

Targeted and whole gland treatments

Treatment planning with nerve sparing, margin localization

Post treatment follow-up scans for confirmation

The Promaxo Advantage In Office MRI



Novel Magnet Formfactor

Truly **open MRI** with an unobstructed field of view and a central aperture for robotic guided interventions



Small Footprint

Compact and portable design is ideally suited for installation in a **standard office or ambulatory surgery center setting**




Standard Wall Power

Operates using **220 VAC, 40 Amps, 60 Hz** and requires minimal facility upgrades



Variably Tuned RF Coil

Unique RF-TX coil design is used to **control the depth** of the field of view



Simple Pulse Sequences

Preprogramed MRI pulse sequences built for our unique MRI design and providing strong imaging contrast

Promaxo MRI is Validated



Use MR-Guidance to detect **clinically significant** prostate cancer



MR-Guided Targeting means **improved accuracy** and **less cores** vs systematic biopsy



400+ patients, **80+** systems and clinical utilization demonstrated through **20+** publications



Patient Motion

Average relative patient movement:
0.855 mm


The relative motion quantified between the template and the prostate



Registration

Average target registration error:
1.87 mm

A1.5T MRI and Promaxo MRI scans co-registered by 4 prostate MRI experts



Navigation

Error from target to core center:
2.57 mm

Projected cores vs ground truth on 1.5T images identified by 4 urologists

Industry Leading Capabilities


Differentiated by accessibility, versatility, and affordability

Complete Platform Offering with Best-in-Class Features



-Portable MRI

- Slim footprint
- Physician & patient friendly
- AI-enhanced imaging
- Platform technology



AI Tissue Characterization⁽¹⁾

- Enables Computer Aided Diagnostics (CAD)⁽¹⁾
- Adaptive treatment planning⁽¹⁾

Customer-validated, Highly Differentiated Offering

Cost Effective

Practice Friendly

Adaptable

- **Single sided form factor** design enabled by strong underlying technology
- The system will incorporate conventional **robotics (est. 2024)** for MRI guided interventional procedures
- **Low cost** of acquisition, maintenance, and operation
- **Easy to use, small footprint and quiet operation** and no significant build outs
- Improved patient experience with **non-invasive imaging** and guidance
- The platform nature of the device enables a physician to perform **adaptable and versatile** image-guided diagnostics and robotic interventions

Partners Across All Customer Segments



Total Patient Care Management

"Now I can bring all in-house. For patients, it makes the whole experience so much easier"

- Dr. Rahul Mehan, MD, Urologist at East Valley Urology

Screening⁽¹⁾

Use Promaxo's AI-based tissue characterization to identify suspicious lesions



Diagnostic Imaging⁽¹⁾

The Promaxo MRI may be used for additional indications



MRI Guided Biopsy

Use Promaxo MRI to guide targeted prostate biopsies



MRI Guided Treatment

Use Promaxo MRI to plan and perform targeted prostate cancer treatment



Patient Follow-up

Perform repeat targeted prostate interventions & track patient care longitudinally





- Promaxo manages the **complete** patient care **pathway**
- To date successfully completed cryoablation and Irreversible Electroporation (IRE). Laser ablation and HIFU are being explored actively
- Follow-up of patients on Active Surveillance seamlessly. Promaxo provides options to re-biopsy complementary parts of the prostate

⁽¹⁾ Currently Works in Progress. Not available as products



Promaxo Biopsy Clinical Workflow





Procedure Planning

Confidential & Proprietary Information





Simple Procedure Planning





PATIENT NAME: JAMES WILLIAMS DOB: 12/12/1988 ID: PROMAXO STUDY DATE: 2024-01-14 19:06:03 mp-MRI: 2023-12-10 TEMPLATE: CIVCO 17G 18G

VOL: 117.2 cc LWH: (7.0, 6.1, 5.4) cm







VIEW ON

PROMAXO
IMPORTED

NEEDLE

Bard MC1820 18G ▼

Units in cm

ADD TARGET

FINISH

PI-RADS	Description
4	T2 hypo & mod diff restriction
5	Early extra-cap extension

RADIOLOGY NOTES

Total Targets: 5

Grid	Depth	Region	
J 4	6.86	L-Apex-Pos	✘
J 3	6.86	LLat-Apex-Pos	✘
C 3	7.21	RLat-Apex-Pos	✘
D 4	7.21	R-Apex-Pos	✘
E 3	7.21	R-Apex-Pos	✘



Copyright © 2024 Promaxo. All rights reserved.

First MRI guided Focal Therapy


Kearney Urology - Nebraska



Garrett D. Pohlman, MD • 1st
Urologist | Host, Prostate Health Podcast | Urol...
7h • Edited •

Another first at Kearney Urology Center! We feel very fortunate to be involved in the world's first In-Office Transperineal MRI Targeted Focal Therapy Cryoablation for Prostate Cancer today. Thanks to the teams at [Promaxo](#) and [Wasatch Medical Specialties](#) for all of your hard work in helping make this service a reality for our patients. There are numerous advantages to being able to offer focal treatment for prostate cancer in the office setting. Definitely a win/win including but not limited to minimal side effects, less cost to the patient, and better reimbursement for the Urologist.

Midtown Urology - Atlanta



Promaxo's MRI-guided treatment revolutionizes longitudinal care with precise lesion intervention, maximizing patient well-being. – Dr. Bennett

Clinical Superiority Planning

“Promaxo’s platform technology has allowed me to identify cancer that a standard TRUS biopsy would have otherwise missed” - John Adams, MD, Urologist at Mississippi Urology

Clinical Superiority Over the Standard of Care⁽¹⁾

Promaxo targeted TP biopsy (2-4 cores)



J. Bennett, M.D. &
N. Shore, M.D.

Bi-Center Study (ASC)

Cancer Detection Rate⁽¹⁾

75%


J. Bennett, M.D.

Midtown Urology (ASC)

Cancer Detection Rate⁽¹⁾

77%

Standard of care TRUS biopsy (12 cores)



J. Adams, M.D.⁽¹⁾ &
B. Chughtai, M.D.⁽²⁾

⁽¹⁾Mississippi Urology

⁽²⁾Weill-Cornell

Identified **more** clinically
significant cancers
(**>3+3**)⁽¹⁾

23%

J. Adams, M.D.⁽¹⁾ &
B. Chughtai, M.D.⁽²⁾

⁽¹⁾Mississippi Urology

⁽²⁾Weill-Cornell

Upstaged Final Diagnosis
over SOC⁽¹⁾

33%

Leadership Team

Promaxo's management team is comprised of experienced professionals with expertise across relevant healthcare sectors



Amit Vohra, PhD, MBA
Founder, President & CEO

- 20+ years as a serial entrepreneur and business strategist
- History of successful ventures in healthcare and technology startups, bringing novel ideas from the ground research phase to commercialization
- Board member and advisor to healthcare technology startups



Dinesh Kumar, PhD, MBA
Chief Operations Officer

- 20+ years as a medical device executive and serial entrepreneur, bringing numerous Class-II and Class-III devices to market, including the first MR-TRUS fusion device for targeted biopsies
- Medical expertise spanning across multiple specialties
- Board member and advisor to healthcare technology startups



Srirama (Sri) Venkataraman, PhD, MBA
Chief Innovation Officer

- 25+ years experience introducing novel MR technologies and clinical programs, ensuring seamless customer adoption
- Launched market-leading Ultrasound/Fusion technologies with Philips Healthcare
- Previously held leadership roles at Philips Healthcare and Stryker



Prithipal Sethi, M.D.
Chief Medical Officer

- 20+ years experience as a board-certified urologist
- CEO and practicing urologist at Golden State Urology
- Specializes in new and emerging treatments for prostate BPH and is a leader in minimally invasive prostate procedures



Chad Zaring
Chief Commercial Officer

- 25+ years experience as a Commercial Sales and Business Development Executive
- Previously VP of Sales at Intuitive Surgical and Mazor Robotic, spearheading Mazor's successful acquisition by Medtronic



Aleksandar Nacev, PhD
Chief Technology Officer

- 15+ years extensive experience in compact magnetic resonance systems and magnetic nanoparticles for drug delivery
- Accomplished executive and team leader
- 240+ patents, 74+ peer-reviewed publications and presentations, cited 1200+ times

KOL and End Users Testimonials



David Samadi, MD
St. Francis Hospital

“Promaxo's portable low-field MRI provides a valuable non-invasive, fully transperineal approach to intervene and treat prostate cancer. It is a significant addition to my mission to prevent men from succumbing to this curable disease.”



Ketan Badani, MD
Mount Sinai

“The Promaxo MRI is a revolutionary technology. It is simple to use, even for physicians and staff with no prior experience. Importantly, my team was able to start performing MR to MR biopsies with reliable precision immediately.”

"My Promaxo MRI procedure was so easy and less invasive compared to a traditional biopsy."

Promaxo Patient



Garrett Pohlman, MD
Kearney Urology

“Bringing the Promaxo MRI into the clinical setting made sense because it is less costly to the patient and offers better reimbursement for the provider.”

"I cannot thank my urologist and oncologist enough. Their careful care has added years of good health to my life."

Promaxo Patient



Vijay Goli, MD
Las Vegas Urology

“Transitioning to the Promaxo MRI has revolutionized my approach to prostate interventions. The use of an in-office MRI to target lesions has not only led to significant improvements in our clinical outcomes, but it also heightened patient safety by minimizing the risk of infections. It's a game-changer for our practice and our patients' well-being.”




James K. Bennett, MD
Midtown Urology

“In my community urology practice, the straightforwardness of Promaxo's MRI-guided transperineal biopsy workflow has empowered me to precisely target lesions, resulting in an impressive 77% cancer detection rate, ultimately making a significant impact on my patients' well-being.”


Rapid Commercial Traction

90 Customers Across All Customer Segments

Sales in 30 States and Virgin Islands



BROWN



Note: Logos are only for selected customers that are available

Collaboration & Partnership with Leading Academic & Research Institutions




MASSACHUSETTS
GENERAL HOSPITAL



HARVARD
MEDICAL SCHOOL



Department of Radiology
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH



Harvard-MIT
Health Sciences & Technology



Massachusetts
Institute of
Technology



Thank You

